Dr. Reddy’s Laboratories is currently buying and selling at Rs. 2531.10, up by means of 7.Forty points or 0.29% from its preceding remaining of Rs. 2523.70 at the BSE.

The scrip opened at Rs. 2530.10 and has touched a excessive and coffee of Rs. 2554.90 and Rs. 2521.00 respectively. So far 6930 stocks have been traded on the counter.

The BSE organization ‘A’ stock of face value Rs. 5 has touched a 52 week excessive of Rs. 2875.00 on 04-Feb-2019 and a fifty two week low of Rs. 1888.00 on 21-May-2018.

Last one week excessive and low of the scrip stood at Rs. 2685.00 and Rs. 2065.30 respectively. The contemporary market cap of the business enterprise is Rs. 41908.Seventy eight crore.

The promoters maintaining within the company stood at 26.77%, while Institutions and Non-Institutions held forty five.67% and 13.94% respectively.

Dr. Reddy’s Laboratories together with its subsidiaries, has re-released Buprenorphine and Naloxone Sublingual Film, 2 mg/zero.5 mg, four mg/1 mg, eight mg/2 mg, and 12 mg/3 mg, a healing equivalent well-known version of Suboxone (buprenorphine and naloxone) sublingual film, in the United States marketplace.

The re-release comes at the heels of a good decision issued by way of the USA Court of Appeals for the Federal Circuit concluding that Indivior had now not proven that it’s miles in all likelihood to be triumphant on its declare that Dr. Reddy’s product infringes US Patent.